Skip to main content

ConnectOne Bancorp, Inc. Reports Third Quarter 2025 Results

Credit Trends Remain Solid Net Interest Margin Widening as Expected Declares Common and Preferred Dividends ENGLEWOOD CLIFFS, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today reported net income (loss) available to common stockholders of $39.5 million for the third quarter of 2025 compared with $(21.8) million for the second quarter of 2025 and $15.7 million for the third quarter of 2024. Diluted earnings (loss) per share were $0.78 for the third quarter of 2025 compared with $(0.52) for the second quarter of 2025 and $0.41 for the third quarter of 2024. On June 1, 2025, the merger with The First of Long Island Corporation (“FLIC”) was completed, thus operating results for the second quarter include one month of...

Continue reading

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarterFull-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026Management to host conference call today, October 30, 2025, at 8:00 a.m. ETFLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) —  Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “Our performance this quarter reinforces our belief in the strength...

Continue reading

Allegro MicroSystems Reports Second Quarter 2026 Results

Sales Increased 14% Year-Over-Year to $214 Million MANCHESTER, N.H., Oct. 30, 2025 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq: ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its second quarter ended September 26, 2025. “We delivered strong second quarter results, with sales of $214 million, up 14% year-over-year, and led by growth in both e-Mobility and Industrial & Other, increasing 21% and 23% year-over-year, respectively. Non-GAAP EPS was $0.13, increasing more than 60% year-over-year,” said Mike Doogue, President and CEO of Allegro. “We saw broad strength in second quarter Automotive sales with growth in e-Mobility and Other Auto, while data center delivered record sales to...

Continue reading

Banco Santander-Chile Announces Third Quarter 2025 Earnings

SANTIAGO, Chile, Oct. 30, 2025 (GLOBE NEWSWIRE) — Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its results1 for the nine-month period ended September 30, 2025, and third quarter 2025 (3Q25). Solid financial performance with a ROAE2 of 24.0% in 9M253 As of September 30, 2025, the Bank’s net income attributable to shareholders totaled $798 billion ($4.23 per share and $1.76 per ADR), representing a 37.3% increase YoY4, with an ROAE of 24.0% in 9M25 compared to a ROAE of 18.2% in 9M245. The increase in results is explained by growth in the Bank’s main revenue lines. Operating income increased 14.8% YoY, driven by a better interest and readjustment margin and higher fees and results from financial transactions. Strong recovery of NIM6, reaching 4.0% in 9M25 Net interest income and readjustments (NII)...

Continue reading

Option Care Health Announces Financial Results For the Third Quarter Ended September 30, 2025

BANNOCKBURN, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (Year-over-year comparisons unless otherwise noted)Net revenue of $1,435.0 million, up 12.2% Gross profit of $272.9 million, up 6.3% Net income of $51.8 million, down 3.8% GAAP diluted earnings per share of $0.32, up 3.2% Adjusted EBITDA of $119.5 million, up 3.4% Adjusted diluted earnings per share of $0.45, up 9.8% YTD cash provided by operating activities of $222.6 million Repurchased $62.5 million of stock in the quarter Term loan expanded $49.6 million, and interest rate reducedJohn...

Continue reading

Malibu Boats, Inc. Announces First Quarter Fiscal 2026 Results

LOUDON, Tenn., Oct. 30, 2025 (GLOBE NEWSWIRE) — Malibu Boats, Inc. (Nasdaq: MBUU) today announced its financial results for the first quarter ended September 30, 2025. First Quarter Fiscal 2026 Highlights Compared to First Quarter Fiscal 2025:Net sales increased 13.5% to $194.7 million Unit volume increased 10.3% to 1,129 units Gross profit decreased 1.0% to $27.9 million GAAP net loss decreased 86.2% from a net loss of $5.1 million to a net loss of $0.7 million GAAP net loss available to Class A Common Stock per share (diluted) decreased 84.0% from a net loss of $0.25 per share to a net loss of $0.04 per share Adjusted EBITDA increased 19.1% to $11.8 million Adjusted net income per share increased 114.3% to $0.15 per share on a basic weighted-average share count of 19.3 million shares of Class A Common Stock“We delivered...

Continue reading

LKQ Corporation Announces Results for Third Quarter 2025

Simplified Portfolio with Successful Closing on Sale of Self Service Segment Returned $118 Million of Capital to Shareholders; $40 Million of Share Repurchases and $78 Million in Cash Dividends Raised Midpoint and Narrowed Range for Full Year 2025 EPS Outlook Following Sale of Self Service ANTIOCH, Tenn., Oct. 30, 2025 (GLOBE NEWSWIRE) — LKQ Corporation (Nasdaq: LKQ) today reported third quarter 2025 financial results and updates outlook for 2025 following the sale of the Company’s Self Service segment. For the periods presented, the Company’s Self Service segment, which was sold on September 30, 2025, has been classified as discontinued operations. Unless otherwise noted, the discussion in this earnings release focuses on continuing operations and excludes discontinued operations for all periods presented. Third Quarter...

Continue reading

HII Reports Third Quarter 2025 Results

NEWPORT NEWS, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII) today reported results for the third quarter of fiscal 2025. HighlightsThird quarter revenues were a record $3.2 billion Third quarter net earnings were $145 million or $3.68 diluted earnings per share Completed builder’s sea trials for guided missile destroyer Ted Stevens (DDG 128) Completed initial sea trials of Virginia-Class Submarine Massachusetts (SSN 798) in early OctoberThird Quarter ResultsThird quarter 2025 revenues of $3.2 billion were up 16.1% from the third quarter of 2024, driven by growth at Newport News Shipbuilding, Ingalls Shipbuilding and Mission Technologies. Operating income in the third quarter of 2025 was $161 million and operating margin was 5.0%, compared to $82 million and 3.0%, respectively, in the third quarter of 2024. Segment...

Continue reading

Iceland Seafood International hf: Q3 2025 results and investors presentation

Iceland Seafood will publish its Interim Financial Statement for Q3 2025 after closing of markets on November 13th 2025. This represents a change from the previously scheduled date of November 19th, moving the publication forward by six days. Iceland Seafood will pause hosting a meeting for investors and market participants for Q1 and Q3 until further notice. However, the company will host a meeting for investors and market participants for Q2 (half-year results) and Q4 (full-year results), where management will present and discuss the results.  Dates for those meetings can be found on the company website  www.icelandseafood.com/investors/shareholders/

Continue reading

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales Received 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary IC-MPGN Reported EMPAVELI U.S. net product revenue of $27 million, reflecting strong early launch in C3G and primary IC-MPGN and continued high patient compliance in PNH SYFOVRE® (pegcetacoplan injection) total injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $151 million Cash and cash equivalents of $479 million as of September 30, 2025; existing cash expected to be sufficient to fund business to sustainable profitability Management to host conference call today at 8:30 a.m. ETWALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.